News from Thursday, June 5, 2025
Articles
Hospital Admissions Similar With Commonly Used T2D Regimens
(6/5, Archita Rai, Medscape) reports “One third of patients with type 2 diabetes (T2D) treated with metformin plus one of four common glucose-lowering drugs (insulin glargine U-100, glimepiride, liraglutide, or sitagliptin) experienced hospitalization over a 5-year period, with a small but significant benefit observed with liraglutide over glimepiride.” Full
Respiratory Treatments Hit Hardest By HTA Terminations In England
(6/5, Leela Barham, Pink Sheet) reports “...Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.” Subscription Required
Journals
Comparative Effectiveness of Rivastigmine and Donepezil in Patients With Alzheimer's Disease: A Retrospective Cohort Study
Adeel Abbas Raja, et al.
May 5, 2025, Cureus
Longer Drug Retention of Interleukin-12/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis
Godehard A Scholz, et al.
May 12, 2025, Mayo Clinic Proceedings, Innovations, Quality & Outcomes
Matching-Adjusted Indirect Comparison of Selpercatinib and Pralsetinib in RET Fusion–Positive Non–Small Cell Lung Cancer
Maximilian Hochmair, et al.
June 3, 2025, Future Oncology
Real-World Comparative Outcomes of GLP-1 RA and Semaglutide Prescription among Individuals with Type 2 Diabetes
Maxwell Mayer Salvatore, et al.
June 4, 2025, medRxiv
Events
Webinar: Beyond Surveys: How to Leverage Patient Communities for Real-World Evidence
June 20, 2025
1:00PM EDT